Skip to main content
SpringerLink
Log in
Book cover

Lymphoma pp 267–277Cite as

Posttransplant Lymphomas

  • Chapter
  • First Online:

  • 2352 Accesses

Part of the book series: Current Clinical Oncology ((CCO,volume 43))

Abstract

PTLDs are a heterogeneous group of diseases ranging from reactive hyperplasia to malignant lymphoma that occur in patients after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). PTLD can occur anywhere from weeks to decades after transplantation. Most are Epstein-Barr virus (EBV)-positive. In at least some instances, EBV gene expression appears to drive the lymphoproliferation in an environment of decreased cell-mediated immunity. Treatment may include reducing or changing immunosuppression, rituximab, adoptive T-cell therapy, or cytotoxic chemotherapy. Judicious selection of immunosuppressive agents, early intervention with rituximab, or utilization of EBV-targeted therapies is a promising prevention strategy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Domingo-Domenech E, de Sanjose S, Gonzalez-Barca E, et al. Post-transplant lymphomas: a 20-year epidemiologic, clinical and pathologic study in a single center. Haematologica. 2001;86(7):715–21.

    PubMed  CAS  Google Scholar 

  2. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80(9):1233–43.

    Article  PubMed  CAS  Google Scholar 

  3. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342(8886–8887):1514–6.

    Article  PubMed  CAS  Google Scholar 

  4. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038–46.

    Article  PubMed  Google Scholar 

  5. Davis CL, Wood BL, Sabath DE, Joseph JS, Stehman-Breen C, Broudy VC. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66(12):1770–9.

    Article  PubMed  CAS  Google Scholar 

  6. Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27(20):3354–62.

    Article  PubMed  Google Scholar 

  7. Ghobrial IM, Habermann TM, Macon WR, et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005;79(2):244–7.

    Article  PubMed  Google Scholar 

  8. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis. 2001;3(2):60–9.

    Article  PubMed  CAS  Google Scholar 

  9. Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol. 2000;53(4):248–54.

    Article  PubMed  CAS  Google Scholar 

  10. Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant. 2008;13(6):563–8.

    Article  PubMed  Google Scholar 

  11. Murray PG, Swinnen LJ, Constandinou CM, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood. 1996;87(2):706–11.

    PubMed  CAS  Google Scholar 

  12. Vakiani E, Basso K, Klein U, et al. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol. 2008;26(4):199–211.

    Article  PubMed  CAS  Google Scholar 

  13. Capello D, Gaidano G. Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease. Mediterr J Hematol Infect Dis. 2009;1(2):e2009018.

    PubMed  Google Scholar 

  14. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.

    Article  PubMed  CAS  Google Scholar 

  15. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation. 1995;59(2):240–4.

    PubMed  CAS  Google Scholar 

  16. Cavaliere R, Petroni G, Lopes MB, Schiff D. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010;116(4):863–70.

    Article  PubMed  Google Scholar 

  17. Snanoudj R, Durrbach A, Leblond V, et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplantation. 2003;76(6):930–7.

    Article  PubMed  Google Scholar 

  18. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 1995;85(2):552–65.

    PubMed  CAS  Google Scholar 

  19. Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol. 2005;23(2):61–7.

    Article  PubMed  Google Scholar 

  20. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep. 2010;12(6):383–94.

    Article  PubMed  Google Scholar 

  21. Swerdlow SH. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol. 2007;127(6):887–95.

    Article  PubMed  Google Scholar 

  22. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol. 2000;24(3):375–85.

    Article  PubMed  CAS  Google Scholar 

  23. Sivaraman P, Lye WC. Epstein-Barr virus-associated T-cell lymphoma in solid organ transplant recipients. Biomed Pharmacother. 2001;55(7):366–8.

    Article  PubMed  CAS  Google Scholar 

  24. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis. 2001;3(2):70–8.

    Article  PubMed  CAS  Google Scholar 

  25. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5(12):2894–900.

    Article  PubMed  CAS  Google Scholar 

  26. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001;72(6):1012–9.

    Article  PubMed  CAS  Google Scholar 

  27. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.

    Article  PubMed  CAS  Google Scholar 

  28. Meijer E, Slaper-Cortenbach IC, Thijsen SF, Dekker AW, Verdonck LF. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique. Bone Marrow Transplant. 2002;29(4):335–9.

    Article  PubMed  CAS  Google Scholar 

  29. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208–16.

    PubMed  CAS  Google Scholar 

  30. Beveridge T, Krupp P, McKibbin C. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy. Lancet. 1984;1(8380):788.

    Article  PubMed  CAS  Google Scholar 

  31. Ganschow R, Schulz T, Meyer T, Broering DC, Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. J Pediatr Gastroenterol Nutr. 2004;38(2):198–203.

    Article  PubMed  CAS  Google Scholar 

  32. Dayton JD, Richmond ME, Weintraub RG, Shipp AT, Orjuela M, Addonizio LJ. Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric heart transplant patients. J Heart Lung Transplant. 2011;30(4):420–5.

    Article  PubMed  Google Scholar 

  33. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant. 2005;5(12):2954–60.

    Article  PubMed  CAS  Google Scholar 

  34. Cen O, Longnecker R. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt’s lymphoma. Mol Cancer Ther. 2011;10(4):679–86.

    Article  PubMed  CAS  Google Scholar 

  35. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352(13):1317–23.

    Article  PubMed  CAS  Google Scholar 

  36. Martin PJ, Hansen JA, Anasetti C, et al. Treatment of acute graft-versus-host disease with anti-CD3 monoclonal antibodies. Am J Kidney Dis. 1988;11(2):149–52.

    PubMed  CAS  Google Scholar 

  37. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990;323(25):1723–8.

    Article  PubMed  CAS  Google Scholar 

  38. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7(11):2619–25.

    Article  PubMed  CAS  Google Scholar 

  39. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107(8):3053–7.

    Article  PubMed  CAS  Google Scholar 

  40. Leblond V, Dhedin N, Mamzer Bruneel MF, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001;19(3):772–8.

    PubMed  CAS  Google Scholar 

  41. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37(2):954–5.

    Article  PubMed  CAS  Google Scholar 

  42. Phan TG, O’Neill BP, Kurtin PJ. Posttransplant primary CNS lymphoma. Neuro Oncol. 2000;2(4):229–38.

    PubMed  CAS  Google Scholar 

  43. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood. 2000;96(13):4055–63.

    PubMed  CAS  Google Scholar 

  44. Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin’s lymphoma. Clin Cancer Res. 2006;12(2):460–4.

    Article  PubMed  CAS  Google Scholar 

  45. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002;94(21):1614–9.

    Article  PubMed  CAS  Google Scholar 

  46. Stevens SJ, Verschuuren EA, Verkuujlen SA, Van Den Brule AJ, Meijer CJ, Middeldorp JM. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leuk Lymphoma. 2002;43(4):831–40.

    Article  PubMed  Google Scholar 

  47. Swinnen LJ, LeBlanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation. 2008;86(2):215–22.

    Article  PubMed  CAS  Google Scholar 

  48. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncology. 2012;13(2):196-206.

    Google Scholar 

  49. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71(8):1076–88.

    Article  PubMed  CAS  Google Scholar 

  50. Boratynska M, Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int. 2008;21(6):605–8.

    Article  PubMed  Google Scholar 

  51. Alberu J, Pascoe MD, Campistol JM, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011;92(3):303–10.

    Article  PubMed  CAS  Google Scholar 

  52. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86(9):3333–40.

    PubMed  CAS  Google Scholar 

  53. Kew 2nd CE, Lopez-Ben R, Smith JK, et al. Postransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation. 2000;69(5):809–14.

    Article  PubMed  Google Scholar 

  54. Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011;96(7):1067–71.

    Article  PubMed  Google Scholar 

  55. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. Haematologica. 2007;92(11):1489–94.

    Article  PubMed  CAS  Google Scholar 

  56. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5(12):2901–6.

    Article  PubMed  CAS  Google Scholar 

  57. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6(3):569–76.

    Article  PubMed  CAS  Google Scholar 

  58. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. 2005;23(27):6481–8.

    Article  PubMed  CAS  Google Scholar 

  59. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330(17):1185–91.

    Article  PubMed  CAS  Google Scholar 

  60. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11(5):383–92.

    Article  PubMed  CAS  Google Scholar 

  61. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549–55.

    PubMed  CAS  Google Scholar 

  62. De Angelis B, Dotti G, Quintarelli C, et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009;114(23):4784–91.

    Article  PubMed  Google Scholar 

  63. Brewin J, Mancao C, Straathof K, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of ­posttransplantation lymphoproliferative disease. Blood. 2009;114(23):4792–803.

    Article  PubMed  CAS  Google Scholar 

  64. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4): 1123–31.

    Article  PubMed  CAS  Google Scholar 

  65. Moosmann A, Bigalke I, Tischer J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115(14):2960–70.

    Article  PubMed  CAS  Google Scholar 

  66. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571–8.

    Article  PubMed  CAS  Google Scholar 

  67. Chen F, Yamane M, Inoue M, et al. Less maintenance immunosuppression in lung transplantation following hematopoietic stem cell transplantation from the same living donor. Am J Transplant. 2011;11(7):1509–16.

    Article  PubMed  CAS  Google Scholar 

  68. Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224–30.

    Article  PubMed  CAS  Google Scholar 

  69. Holmes MV, Caplin B, Atkinson C, et al. Prospective monitoring of Epstein-Barr virus DNA in adult renal transplant recipients during the early posttransplant period: role of mycophenolate mofetil. Transplantation. 2009;87(6):852–6.

    Article  PubMed  CAS  Google Scholar 

  70. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation. 2002;74(3):367–72.

    Article  PubMed  Google Scholar 

  71. Bakker NA, Verschuuren EA, Erasmus ME, et al. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation. 2007;83(4):433–8.

    Article  PubMed  Google Scholar 

  72. Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation. 2009;87(8):1240–5.

    Article  PubMed  CAS  Google Scholar 

  73. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364–9.

    Article  PubMed  Google Scholar 

  74. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Johns Hopkins University School of Medicine, 1650 Orleans, 21287, Baltimore, MD, USA

    Jennifer A. Kanakry MD

  2. Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans, 21287, Baltimore, MD, USA

    Yvette L. Kasamon MD

  3. Division of Hematologic Malignancies, Department of Oncology, Johns Hopkins School of Medicine, 1650 Orleans, 21287, Baltimore, MD, USA

    Richard F. Ambinder MD, PhD

Authors
  1. Jennifer A. Kanakry MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yvette L. Kasamon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard F. Ambinder MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard F. Ambinder MD, PhD .

Editor information

Editors and Affiliations

  1. Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Anas Younes

  2. Service d'Hematologie, CHU Lyon-Sud, chemin du Grand Revoyet, Pierre Bénite, 69310, France

    Bertrand Coiffier

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kanakry, J.A., Kasamon, Y.L., Ambinder, R.F. (2013). Posttransplant Lymphomas. In: Younes, A., Coiffier, B. (eds) Lymphoma. Current Clinical Oncology, vol 43. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-408-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-408-1_17

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-407-4

  • Online ISBN: 978-1-62703-408-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation